Transbronchial fine-needle aspiration, epidermal growth factor receptor mutations, and the Scorpion's touch

Chest

Volumn 131, Issue 6, 2007, Pages 1619-1620

  Zander, Dani S ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ASPIRATION BIOPSY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC PROCEDURE; EDITORIAL; EGFR GENE; GENE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LUNG CANCER; PRIORITY JOURNAL; PROGNOSIS; SCORPION AMPLIFICATION RERFRACTORY MUTATION SYSTEM; SENSITIVITY AND SPECIFICITY; TECHNIQUE; TRANSBRONCHIAL BIOPSY; TUMOR DIAGNOSIS;

EID: 34250809617     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-0386     Document Type: Editorial

References (12)

1. Horiike A, Kimura H, Nishio K, et al. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest 2007; 131:1628-1634
2. Thelwell N, Millington S, Solinas A, et al. Mode of action and application of Scorpion primers to mutation detection. Nucleic Acids Res 2000; 28:3752-3761
3. Whitcombe D, Theaker J, Guy SP, et al. Detection of PCR products using self-probing amplicons and fluorescence. Nat Biotechnol 1999; 17:804-807
4. Carlson RW, Moeuch SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006; 4(Suppl 3):S1-S22
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139
6. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth lactor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97:643-655
7. Chou TY, Chiu CH, Li LH, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11:3750-3757
8. Tomizawa Y, Iijima H, Sunaga N, et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11:6816-6822
9. Sakurada A, Shepherd FA, Tsao MS. Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. Clin Lung Cancer 2006; 7(Suppl 4):S138-S144
10. Brown RE. Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Rev Proteomics 2005; 2:337-348
11. Sarries C, Haura EB, Roig B, et al. Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics 2002; 3:763-780
12. Rosell R, Fossella F, Milas L. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer 2002; 38(Suppl 4):43-49